Century Therapeutics
IPSC
50 hedge funds and large institutions have $335M invested in Century Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 8 closing their positions.
475% more capital inflows, than outflows
Capital inflows: $42.2M | Capital outflows: $7.33M
214% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 7
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
2.29% more ownership
Funds ownership: 36.39% → 38.69% (+2.3%)
2% more funds holding
Funds holding: 49 → 50 (+1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$11.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.72M |
| 3 |
BlackRock
New York
|
+$3.36M |
| 4 |
Morgan Stanley
New York
|
+$2.15M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$1.88M |
| 2 |
Millennium Management
New York
|
-$1.74M |
| 3 |
Woodline Partners
San Francisco,
California
|
-$789K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$755K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$605K |
IPSC Hedge Fund Activity: Q4 2021 in Review
50 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q4 2021, worth a combined $335M — down 32% from $496M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IPSC positions and 8 closed out — a net gain of 2 holders — while 22 added to existing stakes and 7 trimmed.
The largest buyer was Marshall Wace, adding an estimated $11.1M. The largest seller was OrbiMed, cutting an estimated $1.88M.
- 50 institutional investors held Century Therapeutics (IPSC) as of Q4 2021, up from 49 in Q3 2021.
- Funds reported $335M of Century Therapeutics stock for Q4 2021, down 32% quarter-over-quarter.
- 10 funds opened new Century Therapeutics positions in Q4 2021 and 8 closed out, a net change of +2 holders.
- The largest Century Therapeutics buyer in Q4 2021 was Marshall Wace, an estimated $11.1M added.
- The largest Century Therapeutics seller in Q4 2021 was OrbiMed, an estimated $1.88M sold.
Based on aggregated 13F filings for Q4 2021.